Plain-English translation of NCT05759572 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a targeted cancer medication, works better when combined with two other standard treatments (a CDK4/6 inhibitor called and hormone therapy) for women with a specific type of advanced breast cancer. Right now, doctors typically use the hormone therapy and CDK4/6 inhibitor together, but this study wants to see if adding improves results. You would receive the medication as a first treatment, meaning before trying other therapies.
Some women with this type of breast cancer don't respond well enough to current treatments, or their cancer comes back. Researchers believe that this medication might work better when added to the existing combination to help more patients live longer and healthier lives.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be placed into one of two groups: one group will receive , , and hormone therapy together, while the other group will receive and hormone therapy without . You will take these medications regularly (likely by mouth) and attend visits to have your blood tested, imaging scans, and overall health checked. The study is ongoing and researchers are still enrolling patients, so your exact schedule will be discussed with the research team once you enroll.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Fudan University
Collaborators
Peking University Cancer Hospital & Institute, First Hospital of China Medical University
Enrollment target
~145 participants
Started
February 2023
Primary completion
November 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Sex
Female only
Last updated on clinicaltrials.gov in February 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zhimin Shao
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.